PONTE VEDRA, Fla., Dec. 11, 2025 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition...
Pappas Capital targets $200M at next generation of Asian innovation
Pappas Capital's Asia Innovation Ventures is a $200M fund targeting next generation technologies in Asia. The fund was more than two years in the making and is a way to tap into innovation in China, Hong Kong and Singapore.
